ALDH2 and acute myeloid leukemia: Drugs that inhibit both ALDH1A1 and ALDH2 enzymes are potential preclinical development candidates for AML, and our results suggest that the simultaneous targeting of both ALDH1A1 and ALDH2 will be more efficacious than targeting either enzyme alone.